On October 19, 2026 Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T an investigational in situ multi-target immunotherapy platform for solid tumors, reported that updated long-term overall survival (OS) data from a Phase 1 trial of SYNC-T Therapy SV-102 in patients with metastatic prostate cancer will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: Long Term Follow-Up of Overall Survival in Patients with Metastatic Prostate Cancer from the Phase 1 Trial of SYNC-T SV-102 Immunotherapy
Session Category: Metastatic Prostate Cancer
Presentation Number: 2247P
Date/Time: Friday, October 23, 2026, 15:15–16:10 CEST
Presenting Author: Carlos Vargas, M.D., Hospital Diomed, Mexico City, Mexico
The data will be presented as Syncromune continues to advance the ongoing, multicenter, Phase 2a LEGION-100 trial (NCT06533644), which is evaluating SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC).
Abstracts accepted for presentation will be published online via the ESMO (Free ESMO Whitepaper) website on Monday, October 19, 2026. All accepted abstracts will be published online three weeks after the congress in the ESMO (Free ESMO Whitepaper) Congress 2026 Abstract Book, a supplement to ESMO (Free ESMO Whitepaper)’s official journal, Annals of Oncology.
(Press release, Syncromune, OCT 19, 2026, View Source [SID1234673597])